A subsequently larger survey of 8551 lung adenocarcinoma patients from a US‐based genomic profiling database revealed that ERBB2 TMD mutations are very rare at a frequency of 0.18%. This evidence concerns the gene ERBB2 and lung adenocarcinoma.